Research programme: inflammation therapy - Amylin Pharmaceuticals/BioSeek

Drug Profile

Research programme: inflammation therapy - Amylin Pharmaceuticals/BioSeek

Latest Information Update: 15 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer BioSeek
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 15 Jun 2010 This collaborative programme is still in active development
  • 14 Nov 2008 Two anti-inflammatory peptides licensed to BioSeek worldwide
  • 28 May 2007 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top